Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2018
NCT03588429
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine

Active Ingredients

Drugs in Phase 4 Trials (1)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (2)

isoflurane (forane) (1 trial)

sevoflurane (ultane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 4)

Ischemia (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3